Kobata M, Takeda K, Taguchi M, Okutani H, Ide T, Kido A
Anesth Pain Med. 2025; 14(6):e150055.
PMID: 40078644
PMC: 11895794.
DOI: 10.5812/aapm-150055.
Mosleh B, Schwarz S, Cho A, Sinn K, Steindl A, Zochbauer-Muller S
Thorac Cancer. 2025; 16(5):e70024.
PMID: 40066644
PMC: 11894436.
DOI: 10.1111/1759-7714.70024.
Barreto I, Franckenberg S, Frauenfelder T, Opitz I, Lauk O
JTCVS Open. 2025; 23:318-325.
PMID: 40061543
PMC: 11883679.
DOI: 10.1016/j.xjon.2024.10.012.
Chang M, Matnurov E, Wu C, Arakelyan J, Choe H, Kushnarev V
J Am Chem Soc. 2025; 147(9):7908-7920.
PMID: 39992709
PMC: 11887451.
DOI: 10.1021/jacs.4c17966.
Messori A, Trippoli S, Piragine E, Veneziano S, Calderone V
Cancers (Basel). 2025; 17(3).
PMID: 39941870
PMC: 11815993.
DOI: 10.3390/cancers17030503.
Prognostic Stratification of Epithelioid Pleural Mesothelioma Based on the Hippo-TEADs Network.
Poma A, Bruno R, Petrini I, Di Stefano I, Celi A, Sbrana A
Cancers (Basel). 2025; 17(3).
PMID: 39941836
PMC: 11815884.
DOI: 10.3390/cancers17030469.
Malignant Pleural Mesothelioma: A 2025 Update.
Cardillo G, Waller D, Tenconi S, Di Noia V, Ricciardi S
J Clin Med. 2025; 14(3).
PMID: 39941672
PMC: 11818641.
DOI: 10.3390/jcm14031004.
Immune checkpoint inhibitors in the treatment of pleural mesothelioma: insights from real-world data.
Kanayama M, Manabe T, Yoshimatsu K, Oyama R, Matsumiya H, Mori M
Int J Clin Oncol. 2025; .
PMID: 39937425
DOI: 10.1007/s10147-025-02706-4.
Exploring RNA cargo in extracellular vesicles for pleural mesothelioma detection.
Kraft A, Kirschner M, Orlowski V, Ronner M, Bodmer C, Boeva V
BMC Cancer. 2025; 25(1):212.
PMID: 39920655
PMC: 11804012.
DOI: 10.1186/s12885-025-13617-y.
Follow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study-FLORA.
Douma L, Hofman M, Zwierenga F, Zondervan T, Buma A, Schouwink H
ESMO Open. 2025; 10(2):104123.
PMID: 39842244
PMC: 11794158.
DOI: 10.1016/j.esmoop.2024.104123.
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in the Chinese healthcare system.
Lang W, He Y, Hou C, Li H, Jiang Q, Mei L
Front Pharmacol. 2025; 15():1402423.
PMID: 39840092
PMC: 11746052.
DOI: 10.3389/fphar.2024.1402423.
Salvage Pleurectomy/Decortication After Immunotherapy for Sarcomatoid Malignant Pleural Mesothelioma.
Kajiyama K, Taira A, Takenaka M, Kuroda K, Kusano M, Nawata A
Ann Thorac Surg Short Rep. 2025; 1(1):121-123.
PMID: 39790533
PMC: 11708474.
DOI: 10.1016/j.atssr.2022.07.004.
Myeloid Cell Mobilization and Recruitment by Human Mesothelioma in NSG-SGM3 Mice.
Shindyapin V, Gubernatorova E, Gorshkova E, Chicherina N, Sysonov F, Yakovleva A
Cells. 2025; 13(24.
PMID: 39768223
PMC: 11675005.
DOI: 10.3390/cells13242135.
Surgical indications for pleurectomy/decortication in pleural mesothelioma based on the newly revised 9th edition of the tumour-node-metastasis classification.
Kanayama M, Takenaka M, Manabe T, Yoshimatsu K, Oyama R, Matsumiya H
Interdiscip Cardiovasc Thorac Surg. 2024; 40(1.
PMID: 39731746
PMC: 11742126.
DOI: 10.1093/icvts/ivae223.
Prognostic Value of PD-L1, BAP-1 and ILK in Pleural Mesothelioma.
Illini O, Benej M, Lang-Stoberl A, Fabikan H, Brcic L, Sucher F
J Clin Med. 2024; 13(23).
PMID: 39685780
PMC: 11641944.
DOI: 10.3390/jcm13237322.
Malignant pleural mesothelioma treated with cytoreductive video-assisted thoracic surgery plus hyperthermic intrathoracic chemotherapy: a case report.
Li D, Cao Y, Petrella F, Zou Y
J Thorac Dis. 2024; 16(11):8133-8141.
PMID: 39678859
PMC: 11635204.
DOI: 10.21037/jtd-24-1700.
Genome-wide DNA methylation analysis reveals a unique methylation pattern for pleural mesothelioma compared to healthy pleura and other lung diseases.
Vandenhoeck J, Ibrahim J, De Meulenaere N, Peeters D, Raskin J, Hendriks J
Clin Epigenetics. 2024; 16(1):176.
PMID: 39627815
PMC: 11616176.
DOI: 10.1186/s13148-024-01790-z.
Paradoxical Improvement in Malignant Pleural Mesothelioma Outcomes Following Delayed Treatment Initiation.
Kulshrestha A, Taioli E, Wolf A, Flores R, Tuminello S
Cancers (Basel). 2024; 16(22).
PMID: 39594710
PMC: 11592216.
DOI: 10.3390/cancers16223755.
Diagnostic trajectories of patients with rare cancer in the Netherlands: results from a nationwide cross-sectional survey.
Padilla C, de Heus E, Reuvers M, Schrieks M, Engelen V, Grunhagen D
Support Care Cancer. 2024; 32(12):807.
PMID: 39560783
DOI: 10.1007/s00520-024-08998-y.
Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [F]FDG Alternatives.
Guglielmo P, Crivellaro C, Castello A, Della Corte C, Pagano M, Marchesi S
Mol Diagn Ther. 2024; 29(1):55-66.
PMID: 39514167
DOI: 10.1007/s40291-024-00756-4.
